{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:50:19Z","timestamp":1775713819501,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,8]]},"DOI":"10.7759\/cureus.106689","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:09:31Z","timestamp":1775711371000},"source":"Crossref","is-referenced-by-count":0,"title":["Undifferentiated Purpuric and Desquamative Drug Eruption After Pembrolizumab and Empagliflozin Exposure: A Clinicopathologic Diagnostic Pitfall"],"prefix":"10.7759","author":[{"given":"Navanita","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian  J","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","article-title":"Pembrolizumab","author":"Flynn JP","year":"2026","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer L","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al.. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016, 60:210-25. 10.1016\/j.ejca.2016.02.024","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem JE","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19:1579-89. 10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.04.015","article-title":"Incidence of leukocytoclastic vasculitis, 1996 to 2010: A population-based study in Olmsted County, Minnesota","volume":"89","author":"Arora A","year":"2014","unstructured":"Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MD, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: A population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2014, 89:1515-24. 10.1016\/j.mayocp.2014.04.015","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065643","article-title":"Rheumatic immune-related adverse events due to immune checkpoint inhibitors-A 2023 update","volume":"24","author":"Dang QM","year":"2023","unstructured":"Dang QM, Watanabe R, Shiomi M, et al.. Rheumatic immune-related adverse events due to immune checkpoint inhibitors-A 2023 update. Int J Mol Sci. 2023, 24:5643. 10.3390\/ijms24065643","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.05.020","article-title":"Checkpoint inhibitor-associated cutaneous small vessel vasculitis","volume":"4","author":"Castillo B","year":"2018","unstructured":"Castillo B, Gibbs J, Brohl AS, Seminario-Vidal L. Checkpoint inhibitor-associated cutaneous small vessel vasculitis. JAAD Case Rep. 2018, 4:675-7. 10.1016\/j.jdcr.2018.05.020","journal-title":"JAAD Case Rep"},{"key":"ref8","article-title":"AJCC Cancer Staging Manual, 8th ed","author":"Amin MB","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al.. AJCC Cancer Staging Manual, 8th ed. Springer, New York, NY; 2017."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/475827-undifferentiated-purpuric-and-desquamative-drug-eruption-after-pembrolizumab-and-empagliflozin-exposure-a-clinicopathologic-diagnostic-pitfall","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:09:32Z","timestamp":1775711372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/475827-undifferentiated-purpuric-and-desquamative-drug-eruption-after-pembrolizumab-and-empagliflozin-exposure-a-clinicopathologic-diagnostic-pitfall"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.106689","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,8]]}}}